+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database



Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database



Radiation Oncology 13(1): 113



The goal of this study is to evaluate the status and future perspectives of clinical trials on positron emission tomography in prostate cancer for diagnostic or therapeutic as well as for surveillance purposes. The www.ClinicalTrials.gov database was searched on the 20th of January 2017 for all trials containing terms describing "prostate cancer" (prostate, prostatic, malignant, malignancy, cancer, tumor) and "positron emission tomography". In total 167 trials were identified. Trials that included diseases other than PCa were excluded (n = 27; 16%). Furthermore, we excluded trials (n = 4, 2%) withdrawn prior to first patient enrollment. The remaining trials (n = 137, 82%) were selected for further manual classification analysis. One hundred thirty-seven trials were detected and analyzed. Majority of trials were in "active" recruitment status (n = 46, 34%) followed by trials that had been "completed" - (n = 34, 25%) and trials with "closed recruitment but active follow-up" (n = 23, 17%). Phase 1 and 2 comprised 46% of the complete trial portfolio. Locally confined disease was of major interest (n = 46, 34%), followed by metastatic disease - not otherwise specified (n = 43, 13%). Evaluation of PET was the primary goal of the trial in 114 (83%) cases. Most of the trials evaluated only one agent (n = 122, 89%). Choline and PSMA represented two major groups (total 50%) and they were equally distributed across trial portfolio with 25% (n = 34) each. PSMA trials showed the highest average annual growth rate of 56%. The trials were conducted in 17 countries. The scientific community is showing a strong and ever-growing interest in the field and we expect that in the coming years, more phase III trials will be initiated ultimately delivering the required Level 1 evidence.

(PDF emailed within 0-6 h: $19.90)

Accession: 054990765

Download citation: RISBibTeXText

PMID: 29914515

DOI: 10.1186/s13014-018-1057-3


Related references

Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. European Urology Focus 1(2): 173-184, 2015

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. Bju International 120(2): 197-203, 2016

Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative. Journal of Medical Imaging and Radiation Oncology 61(4): 503-505, 2017

68 Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus 2017, 2017

Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients. Molecular Imaging and Biology 7(3): 229-235, 2005

Value of (11C)choline-positron emission tomography for re-staging prostate cancer: A comparison with (18F)fluorodeoxyglucose-positron emission tomography. Journal of Urology 169(4): 1337-1340, 2003

Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. Journal of Urology 169(4): 1337-1340, 2003

Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Science 101(6): 1471-1479, 2010

Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. European Journal of Radiology 81(5): 1002-1006, 2012

New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography. International Urology and Nephrology 49(5): 803-810, 2017

Clinical usefulness of positron emission tomography in prostate cancer. Presse Medicale 36(12 Pt 2): 1794-1806, 2007

Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative (131) I whole-body scan results: A meta-analysis. Head and Neck 38(2): 316-327, 2016

11C-acetate positron emission tomography of prostate cancer First clinical experience. Journal of Nuclear Medicine 42(5 Supplement): 121P, 2001

11C-choline positron emission tomography of prostate cancer First clinical experience. Journal of Nuclear Medicine 41(5 Suppl ): 74P-75P, 2000

Salvage Treatment in Patients With Prostate Cancer Oligorecurrence: Impact of 18-F-Fluorocholine Positron Emission Tomography/Computed Tomography on Clinical Decision Making. International Journal of Radiation Oncology*biology*physics 96(2): E224-E225, 2016